Rock Creek Pharmaceuticals Inc is a United States-based pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine.

Employees

Sector

Pharmaceuticals

More about the company

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

08/12/20	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
06/02/20	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI

Market Cap	153K 132K 124K 113K 212K 14.59M 213K 1.47M 569K 7.44M 576K 563K 23.55M	P/E 2014	-0.87x	P/E 2015	-1.04x
Enterprise Value	20.01M 17.2M 16.19M 14.77M 27.61M 1.9B 27.74M 192M 74.16M 970M 75.11M 73.5M 3.07B	EV / Sales 2014	-	EV / Sales 2015	-
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

08/12/20	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
06/02/20	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI
21/12/18	Motion for Asset Sale Filed by Rock Creek Pharmaceuticals, Inc.	CI
11/01/18	Motion for Asset Sale Approved for Rock Creek Pharmaceuticals, Inc.	CI
27/09/16	Rock Creek Pharmaceuticals, Inc. Filed for Bankruptcy	CI
29/08/16	Rock Creek Pharmaceuticals, Inc. Receives Event of Default Redemption Notice from Hudson Bay Master Fund Ltd. and from Tenor Capital Management on Behalf of Alto Opportunity Master Fund	CI
10/08/16	Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2016	CI
08/07/16	Rock Creek Pharmaceuticals, Inc. Announces Board Changes	CI
08/06/16	Rock Creek Pharmaceuticals, Inc. Reports Earnings results for the First Quarter Ended March 31, 2016	CI
29/03/16	Rock Creek Pharmaceuticals, Inc. announced that it has received $0.5 million in funding.	CI
22/03/16	Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Year Ended December 31, 2015	CI
21/03/16	Rock Creek Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
19/11/15	Rock Creek Pharmaceuticals, Inc. Appoints Robert Scannell as Director	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ROCK CREEK PHARMACEUTICALS, INC.	-.--%	-.--%	-	-	17.04K
ELI LILLY AND COMPANY	+0.03%	-3.09%	+52.20%	+91.69%	1,002B
JOHNSON & JOHNSON	-0.76%	-1.52%	+49.94%	+66.34%	649B
ABBVIE INC.	+0.86%	-3.49%	+19.60%	+68.37%	440B
ROCHE HOLDING AG	-0.80%	+0.06%	+28.73%	+35.45%	346B
NOVARTIS AG	-0.13%	-14.74%	+9.13%	+26.71%	263B
ASTRAZENECA PLC	-1.90%	-2.61%	-2.67%	+7.41%	250B
AMGEN INC.	-0.48%	-10.69%	+39.64%	+50.82%	213B
NOVO NORDISK A/S	-1.06%	-1.70%	-16.73%	-57.36%	201B
GILEAD SCIENCES, INC.	-0.68%	-2.85%	+25.69%	+91.64%	182B
Average	-0.49%	-1.86%	+22.84%	+42.34%	354.37B
Weighted average by Cap.	-0.37%	-2.39%	+32.37%	+57.01%

Rock Creek Pharmaceuticals, Inc. Share Price

Stocks

RCPIQ

US7720812046

Pharmaceuticals

Valuation : Rock Creek Pharmaceuticals, Inc.

Latest news : Rock Creek Pharmaceuticals, Inc.

Analysts' recommendations : Rock Creek Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

	2014	2015
Net sales	-	-
Net income	-38.52M -33.1M -31.16M -28.44M -53.15M -3.66B -53.39M -369M -143M -1.87B -145M -141M -5.91B	-6.84M -5.88M -5.54M -5.05M -9.45M -651M -9.49M -65.59M -25.37M -332M -25.69M -25.14M -1.05B
Net Debt	-45K -38.67K -36.4K -33.22K -62.1K -4.28M -62.38K -431K -167K -2.18M -169K -165K -6.91M	19.86M 17.06M 16.06M 14.66M 27.4M 1.89B 27.53M 190M 73.6M 963M 74.54M 72.93M 3.05B